Comparing two ways to start etoposide for severe HLH
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares two different ways of starting a medicine called etoposide for adults with a severe first episode of HLH (hemophagocytic lymphohistiocytosis), a rare condition where the immune system becomes overactive and damages organs. It looks at whether giving the drug right away or waiting a bit is safer and more effective for people in intensive care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with HLH for the first time.
- You are currently in the intensive care unit (ICU).
- You have at least one organ failure, such as low blood pressure, trouble breathing, kidney problems, or decreased consciousness.
- You have not had etoposide before, and you are not allergic to it or to dexamethasone.
- You are not pregnant, breastfeeding, or planning to get pregnant soon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs for people whose intestinal disease is linked to the Epstein-Barr virus (EBV). It aims to see if this treatment can help control the disease and improve outcomes.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial compares two ways to collect your own stem cells before a transplant in people with non-Hodgkin's lymphoma who are in remission. The goal is to see which method works better for getting enough healthy cells.
Hear when a new Hemophagocytic Lymphohistiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.